The light of hope for breast cancer patients is highly selective, the CDK4/6 inhibitor.

On 28 November, the National List of Essential Health Insurance, Employment Injury and Maternity Insurance Medicines (2024) was published. As a result of this adjustment, hen Shwe medicine was visible and 12 products were successfully adapted through the new version of the National Health Insurance Directory. This outcome is not only an expression of the strength of the Rin Shwe pharmaceutical research and development, but also of the evangelization of many patients, which offers new hope for the treatment of multiple diseases. As part of this adjustment, the Darsili film, an innovative drug of the 1st type of Heinrich medicine (trade name: Irecon) was successfully renewed to the National Health Insurance List through the “Summary Renewal” rule, which is known to be China’s first self-developed high-selective CDK4/6 inhibitor for breast cancer-related treatment. Breast cancer is a malignant tumor that afflicts many women. According to the Global Cancer Epidemiology Report 2024, the incidence and mortality of breast cancer is among the highest among malignant tumours in women, with approximately 2.31 million new cases of breast cancer and 670,000 deaths per year globally. In China, the incidence and mortality of breast cancer has also been rising steadily in recent years, ranking fourth among the causes of cancer deaths. The Dalsili tablet of hydroxysulfonate (trade name: Erecon) is a new category of self-researched 1 drug and the first high-selective CDK4/6 inhibitor developed by China, which was approved for listing by the National Drug Office in December 2021 and approved for the treatment of re-emergence or transferive breast cancer for use in hormonal receptor (HR) positives by the Union of Fluwisss, human skin growth factor receptor 2 (HER2) after negative endocrinic treatment; In June 2023, a combination of aromatic enzyme inhibitors was approved as the initial treatment for hormonal receptor (HR) positives, human skin growth factor (HER2) local later or transferal breast cancer patients. The successful adjustment of 12 products, in particular the renewal of drugs such as the Darsili tablet of hydroxysulfonate, demonstrated the positive contribution of the company in the development of medicines and in safeguarding the rights and interests of patients. A total of 106 products have been incorporated into the national health insurance and 15 innovative medicines have been listed for entry into the health insurance catalogue, which will continue to improve the accessibility and affordability of quality medicines, increase the number of patients in the country who have a chance of survival in the fight against disease, and provide a solid basis for future developments in the field of medicine and for patient health security.